BMS’ neuro renaissance was built on back of Celgene mega-merger

Well-known for its oncology efforts and making recent headlines for a rumored mega merger with AstraZeneca, Bristol Myers Squibb is also dedicating considerable resources to neurological and psychiatric diseases, with a “continuum of care” mindset.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top